Predictive Oncology Inc. (POAI)
Stock Price:
$0.740 USD
0.025 (3.53%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $0.730 -0.010 (-1.35%) Nov 27, 4:31 PM
Key Info
| Market Cap |
13.08M |
| Revenue (ttm) |
1.31M |
| Net Income (ttm) |
-28.67M |
| Shares Out |
17.68M |
| EPS (ttm) |
-3.42 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$0.740 |
| Previous Close |
$0.715 |
| Change ($) |
0.025 |
| Change (%) |
3.53% |
| Day's Open |
0.725 |
| Day's Range |
0.710 - 0.770 |
| Day's Volume |
408,325 |
| 52-Week Range |
0.630 - 5.300 |
More Stats
| Market Cap |
13.08M |
| Enterprise Value |
18.16M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
17.68M |
| Float |
15.30M |
| EPS (basic) |
-6.29 |
| EPS (diluted) |
-3.42 |
| FCF / Share |
-0.85 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
554,388 |
| Short Ratio |
1.11 |
| Short % of Float |
3.62% |
| Beta |
1.75 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
10.02 |
| PB Ratio |
0.99 |
| Revenue |
1.31M |
| Operating Income |
-30.59M |
| Net Income |
-28.67M |
| Free Cash Flow |
-12.87M |
| Net Cash |
-5.08M |
| Net Cash / Share |
-0.29 |
| Gross Margin |
67.36% |
| Operating Margin |
-2,342.03% |
| Profit Margin |
-2,195.10% |
| FCF Margin |
-985.38% |
| ROA |
-24.15% |
| ROE |
-169.76% |
| ROIC |
1,611.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 1.41 | 1.41 | 0.65 | 0.46 | 0.65 | 0.95 | 0.47 | 0.19 | 0.10 | - |
| Revenue Growth | -0.01% | 115.57% | 43.45% | -30.24% | -31.23% | 103.27% | 147.98% | 95.34% | 33454.51% | - |
| Gross Profit | 0.88 | 1.00 | 0.51 | 0.27 | 0.35 | 0.57 | 0.28 | 0.06 | 0.04 | - |
| Operating Income | -26.62 | -8.30 | -6.06 | -6.53 | -4.40 | -6.47 | -8.93 | -7.16 | -4.11 | -2.35 |
| Net Income | -19.39 | -10.09 | -6.00 | -6.53 | -4.79 | -6.83 | -9.41 | -7.42 | -4.49 | -1.35 |
| Shares Outstanding | 2.87 | 1.28 | 0.64 | 0.28 | 0.02 | 0.01 | 0.01 | - | - | - |
| Earnings Per Share | -6.86 | -7.87 | -9.40 | -23.10 | -308.60 | -572.50 | -1,160.00 | -2,063.02 | -3,375.84 | -2,063.02 |
| Operating Cash Flow | -8.73 | -5.29 | -4.46 | -4.38 | -7.49 | -3.37 | -3.86 | -1.18 | -1.78 | -0.82 |
| Capital Expenditures | -0.01 | -0.18 | -0.05 | -0.03 | -0.03 | -0.10 | -0.16 | - | - | - |
| Free Cash Flow | -8.74 | -5.47 | -4.50 | -4.41 | -7.52 | -3.47 | -4.02 | -1.18 | -1.78 | -0.82 |
| Cash & Equivalents | 0.15 | 0.66 | 1.68 | 2.15 | 4.86 | 0.02 | 0.10 | 0.01 | 0.12 | 0.01 |
| Total Debt | 5.53 | 1.63 | - | - | - | 0.94 | 0.28 | 1.17 | 1.69 | 1.07 |
| Net Cash / Debt | -5.37 | -0.98 | 1.68 | 2.15 | 4.86 | -0.92 | -0.18 | -1.16 | -1.56 | -1.06 |
| Assets | 22.38 | 3.71 | 3.62 | 2.81 | 5.63 | 0.90 | 0.59 | 0.37 | 0.45 | 0.17 |
| Liabilities | 11.14 | 3.66 | 0.93 | 1.88 | 1.52 | 6.42 | 3.81 | 3.67 | 3.15 | 2.36 |
| Book Value | 11.23 | 0.05 | 2.69 | 0.92 | 4.11 | -5.52 | -3.22 | -3.30 | -2.70 | -2.19 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Predictive Oncology Inc. |
| Country |
United States |
| Employees |
29 |
| CEO |
Carl Schwartz |
Stock Information
| Ticker Symbol |
POAI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NASDAQ: POAI |
Description
Predictive Oncology provides various healthcare products and services primarily in the United States. The company operates in three segments: Domestic, International, and Helomics. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers STREAMWAY System, a wall-mounted fully automated system that disposes suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers' exposure to infectious fluids collected during surgical and other patient procedures, as well as provides proprietary cleaning fluid and filters for use with STREAMWAY System. The company also provides data and artificial intelligence (AI) driven contract research organization (CRO) services for clinical and translational research; a range of multi-omics assays; and AI driven predictive models for the discovery of targeted therapies. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. The company sells its medical device products directly to hospitals and other medical facilities through employed sales representatives, independent contractors, and distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was founded in 2002 and is based in Eagan, Minnesota.